Related Experiment Video
Updated: May 11, 2026
23:33
The WATCHMAN Left Atrial Appendage Closure Device for Atrial Fibrillation
Published on: February 28, 2012
[Direct oral thrombin inhibitor, "dabigatran"]
1Department of Cerebrovascular Medicine, National Hospital Organization Kyushu Medical Center.
Summary
Dabigatran effectively prevents stroke in atrial fibrillation patients, offering simpler management and lower intracranial bleeding risk compared to warfarin. Adhering to treatment guidelines is crucial for safety.
Area of Science:
- Pharmacology
- Cardiology
- Thrombosis
Context:
- Non-valvular atrial fibrillation (NVAF) poses a significant stroke risk.
- Warfarin, a traditional anticoagulant, has limitations in management and safety.
- Novel oral anticoagulants offer potential improvements in stroke prevention.
Purpose:
- To evaluate the effectiveness and safety of dabigatran for stroke prevention in NVAF patients.
- To compare dabigatran with warfarin in terms of efficacy and bleeding risk.
- To highlight the unique 'hybrid anticoagulation' mechanism of dabigatran.
Summary:
- Dabigatran is an oral direct thrombin inhibitor used for stroke prevention in NVAF at 110 mg or 150 mg twice daily.
- It provides 'hybrid anticoagulation' without inhibiting protein C and S production, unlike warfarin.
- The RE-LY trial demonstrated dabigatran's effectiveness and safety, with significantly lower intracranial bleeding risk than warfarin.
- Dabigatran management is simpler due to no food restrictions, fewer drug interactions, and predictable pharmacokinetics.
Impact:
- Dabigatran offers a safer and more manageable alternative for stroke prevention in NVAF.
- Reduced intracranial bleeding risk improves patient outcomes and reduces healthcare burden.
- Understanding dabigatran's mechanism and management is key to optimizing anticoagulation therapy.
Related Concept Videos
01:18Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
01:29Venous Thrombosis III: Interprofessional Care
Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
01:30Anticoagulant Drugs: Low-Molecular-Weight Heparins
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
01:20Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
01:25Antihypertensive Drugs: Direct Renin Inhibitors
The renin-angiotensin-aldosterone system (RAAS) is an intricate physiological pathway involving numerous enzymes and hormones, including renin, angiotensin-converting enzyme (ACE), angiotensin I and II, and aldosterone. Imbalances within this system increase the production of angiotensin II and aldosterone. Increased angiotensin II levels promote vasoconstriction and blood pressure elevation. Concurrently, higher aldosterone levels stimulate sodium and water reabsorption in the kidneys,...
01:26Directly Acting Muscle Relaxants: Dantrolene and Botulinum Toxin
Directly acting muscle relaxants like dantrolene and botulinum toxin (BoNT) have distinct mechanisms and applications. Dantrolene, a hydantoin derivative, acts on the ryanodine receptor (RYR1) in skeletal muscle cells. RYR1 are calcium channels present at the sarcoplasmic reticulum membrane. In response to excitation, they release calcium ions from the sarcoplasmic reticulum to the cytosol. Calcium promotes actin-myosin-mediated contraction of muscles.
The binding of dantrolene to the RYR1...
The binding of dantrolene to the RYR1...